Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54357
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSharma, Priyanka-
dc.contributor.authorLópez-Tarruella, Sara-
dc.contributor.authorGarcía-Saenz, José Angel-
dc.contributor.authorKhan, Qamar J-
dc.contributor.authorGómez, Henry L-
dc.contributor.authorPrat, Aleix-
dc.contributor.authorMoreno, Fernando-
dc.contributor.authorJerez-Gilarranz, Yolanda-
dc.contributor.authorBarnadas, Agustí-
dc.contributor.authorPicornell, Antoni C-
dc.contributor.authorMonte-Millán, María Del-
dc.contributor.authorGonzález-Rivera, Milagros-
dc.contributor.authorMassarrah, Tatiana-
dc.contributor.authorPelaez-Lorenzo, Beatriz-
dc.contributor.authorPalomero, María Isabel-
dc.contributor.authorGonzález Del Val, Ricardo-
dc.contributor.authorCortés, Javier-
dc.contributor.authorFuentes-Rivera, Hugo-
dc.contributor.authorMorales, Denisse Bretel-
dc.contributor.authorMárquez-Rodas, Iván-
dc.contributor.authorPerou, Charles M-
dc.contributor.authorLehn, Carolyn-
dc.contributor.authorWang, Yen Y-
dc.contributor.authorKlemp, Jennifer R-
dc.contributor.authorMammen, Joshua V-
dc.contributor.authorWagner, Jamie L-
dc.contributor.authorAmin, Amanda L-
dc.contributor.authorO'Dea, Anne P-
dc.contributor.authorHeldstab, Jaimie-
dc.contributor.authorJensen, Roy A-
dc.contributor.authorKimler, Bruce F-
dc.contributor.authorGodwin, Andrew K-
dc.contributor.authorMartín, Miguel-
dc.date.accessioned2021-04-30T11:14:44Z-
dc.date.available2021-04-30T11:14:44Z-
dc.date.issued2018-
dc.identifier.citationClin Cancer Res.2018 12;(24)23:5820-5829es_ES
dc.identifier.issn1557-3265-
dc.identifier.urihttps://hdl.handle.net/20.500.12530/54357-
dc.description.abstractPrognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC.es_ES
dc.language.isoenes_ES
dc.relation.isversionofPreprintes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectTriple-Negative Breast Canceres_ES
dc.subject.meshAdultes_ES
dc.subject.meshAgedes_ES
dc.subject.meshAged, 80 and overes_ES
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolses_ES
dc.subject.meshBiomarkers, Tumores_ES
dc.subject.meshCarboplatines_ES
dc.subject.meshCombined Modality Therapyes_ES
dc.subject.meshDocetaxeles_ES
dc.subject.meshFemalees_ES
dc.subject.meshGenes, BRCA1es_ES
dc.subject.meshGenes, BRCA2es_ES
dc.subject.meshHumanses_ES
dc.subject.meshKaplan-Meier Estimatees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshNeoadjuvant Therapyes_ES
dc.subject.meshNeoplasm Gradinges_ES
dc.subject.meshNeoplasm Metastasises_ES
dc.subject.meshNeoplasm Staginges_ES
dc.subject.meshPrognosises_ES
dc.subject.meshTreatment Outcomees_ES
dc.subject.meshTriple Negative Breast Neoplasmses_ES
dc.titlePathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxeles_ES
dc.typeArtículoes_ES
dc.identifier.pubmedID30061361es_ES
dc.format.volume24es_ES
dc.format.page5820-5829es_ES
dc.description.peerreviewedes_ES
dc.identifier.journalClinical cancer research : an official journal of the American Association for Cancer Researches_ES
dc.identifier.journalabbreviationClin Cancer Reses_ES
dc.contributor.authoraffiliationInstituto de Investigación Sanitaria Gregorio Marañónes_ES
dc.format.number23es_ES
Appears in Collections:Hospitales > H. U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
5820.full.pdf500,3 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.